 VALENCIA, Calif. and MELBOURNE, Australia, Nov. 05, 2020 GLOBE NEWSWIRE -- AVITA Therapeutics, Inc. NASDAQ: RCEL, ASX: AVH, a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that David McIntyre notified the Company of his intention to resign as the Companys Chief Financial Officer in order to pursue life sciences opportunities in his home state of New Jersey. The effective date of his resignation is November 23, 2020. Mr. McIntyre has also agreed to provide consultancy services to the Company through December 31, 2020 so as to support a smooth transition of his responsibilities. The Company wishes to thank David for successfully leading and completing the redomiciliation project during his tenure as well as for his many valuable contributions to AVITAs executive leadership team. 